Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors

Summary

This is a Phase I, First-In-Human, open label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of PUR001, an anti-CD39 monoclonal antibody, in adult patients with advanced solid tumors, as monotherapy. A "3+3" design will be used to determine MTD and RP2D. .

Timeline

Start

2022-04-28

Primary completion

2023-12

Completion

2023-12

Drugs

Indications